Strata Critical Medical 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Q3 2026 revenue increased 50.3% to 74.1 million from 49.3 million in the prior-year period; on a pro-forma basis, revenue increased 8.5% year over year.
- Total gross profit increased 57.9% to 16.8 million, and total gross margin increased 110 basis points to 22.7% from 21.6%.
- Clinical revenue increased 20.3% sequentially, while clinical gross margin declined 50 basis points to 25.6% from 26.1% in Q2 2026, reflecting investments in staff and training and elevated use of part-time providers.
- Logistics revenue decreased 6.9% sequentially and 3.5% year over year; logistics gross margin rose 240 basis points sequentially to 20.8% from 18.4% in Q2 2026.
- Adjusted EBITDA increased to 9.6 million from 4.2 million in Q3 2025 and 7.9 million in Q2 2026, with adjusted EBITDA margin of 13%, compared with 8.5% and 10.9%, respectively.
- GAAP loss from continuing operations was 7.6 million; management attributed it entirely to non-cash transaction-related items.
- Operating cash flow was 9.5 million and free cash flow was 8.6 million; Strata ended Q3 2026 with 41.6 million in cash and short-term investments.
- Strata received 15.3 million in net proceeds from the sale of all Joby earn-out shares and said an additional 27.5 million of potential earn-out consideration could be released in Q1 2027.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, ladies and gentlemen, and welcome to the Strata Critical Medical Fiscal Third Quarter 2026 Earnings Release Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, this call is being recorded. I would now like to turn the conference call over to Matt Schneider, CFO of Clinical Services and Vice President of Finance and Investor Relations.
Matt, you may begin. Thank you for standing by, and welcome to Strata's conference call and webcast for the quarter ended September 30, 2026.
We appreciate everyone joining us today. Before we get started, I would like to remind you of the company's forward-looking statement and safe harbor language. Statements made in this conference call that are not historical facts, including statements about future time periods, may be deemed to constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties, and actual future results may differ materially from those expressed or implied by the forward-looking statements. We refer you to our SEC filings, including our annual report on Form 10-K and our quarterly report on Form 10-Q, each as filed with the SEC, for a more detailed discussion of the risk factors that could cause these differences.
Any forward-looking statements provided during this conference call are made only as of the date of this call. As stated in our SEC filings, Strata disclaims any intent or obligation to update or revise these forward-looking statements, except as required by law. During today's call, we will also discuss certain non-GAAP financial measures, which we believe may be useful in evaluating our financial performance. A reconciliation of the most directly historical comparable consolidated GAAP financial measures to those historical non-GAAP financial measures is provided in our earnings press release and investor presentation. Our press release, investor presentation, and our Form 10-Q and 10-K filings are available on the investor relations section of our website at ir.stratacritical.com. These non-GAAP measures should not be considered in isolation or as a substitute for financial results prepared in accordance with GAAP. Hosting today's call are our co-CEOs, Will Heyburn and Melissa Tomkiel.
I'll now turn the call over to Will.
Thank you, Matt, and good morning, everyone. Our strong third quarter results speak for themselves. Q3 was not only ahead of our guidance, but also showed off Strata's capability to generate significant cash flow with much higher conversion. As more customers turn to our integrated transplant offering for more of their cases, we are demonstrating continued market share gains in clinical services. This helped to drive clinical segment revenue growth of more than 20% sequentially versus Q2 2026. As Melissa will discuss in more detail, our go-to-market is all about creating alignment with our customers' objectives, becoming that trusted long-term partner in a space that's becoming far too complex to go it alone. We saw yet another quarter of sequential margin improvement, driven in large part by achieving our 2027 logistics gross margin target well ahead of plan.
Logistics revenue came in towards the high end of our guidance framework, despite both a larger-than-expected seasonal industry decline during Q3 and a reduction in industry trip distances. We're pleased that following our significant growth and the completion of three acquisitions during Q2, we still saw a reduction in our adjusted SG&A base quarter over quarter. Most importantly, this quarter put a spotlight on the scalability and cash generation potential of our business model, with a record $8.6 million of free cash flow in Q3. We're also pleased to report that we're pacing ahead of the medium-term goals we set out at our investor day last November. Looking ahead to 2027, we believe we're on track to achieve our target high-teens organic adjusted EBITDA growth and 30% plus total adjusted EBITDA growth, including acquisitions as well.
On the M&A front, we're well ahead of plan for 2026, closing on over $6 million of expected annualized adjusted EBITDA at our targeted mid-single-digit valuation multiples. We have a strong pipeline to deploy additional capital at our target valuations, with a focus on opportunities that will further strengthen our strategic position while enhancing our margin and free cash flow conversion profile. Given Strata's improved cash generation, coupled with the receipt of our first Passenger sale earnout, we ended the quarter with roughly $42 million of cash and short-term investments, and that's before our anticipated receipt of an additional $27 million of Passenger sale consideration early next year. As such, we are now in a position both to accelerate beyond our target pace of acquisitions, as well as opportunistically return cash to shareholders.
To that end, today we announced a $20 million share repurchase authorization, allowing us to take advantage of what we see as an attractive valuation for our own stock. In closing, let's bring things back to basics. The underlying driver of our financial performance is simple: better service, architected for efficiency, and delivered in partnership with our customers to prioritize their individual preferences and our shared goal to save more lives. With that, I'll turn the call over to Melissa.
Thanks, Will. It's now been one year since our strategic transformation and the beginning of Strata. As Will just reviewed, the impact of our new strategy to our financial results is self-evident, but I'd like to take a few minutes to focus on our evolving and strengthening customer value proposition. This is what we believe is driving our share gains today and what will continue to fuel our strong growth in the years to come. The fundamental challenge we face with our partners is to increase the supply of donor organs. Demand has only grown. The transplant community has responded to this challenge with innovation in the form of perfusion and other preservation technologies that has led to a significant expansion in the pool of donation after circulatory death, or DCD donors, which now make up over half of all transplants.
With this shift to DCD comes significantly more complexity versus traditional donation after brain death, or DBD donors. Perfusion technology is generally required along with clinicians experienced in its use. Cases take longer, and organs are unusable, which we call a dry run, roughly 30% of the time. As a result, the historical system of relying upon a transplant center's captive clinicians and technology is breaking. America's 250 transplant centers and 50 OPOs simply do not have the national scale required to manage this complexity alone, nor do the patchwork of excellent but regional providers that have historically served the industry. Enter Strata. We have created an integrated platform offering organ recovery, perfusion, logistics, and placement with the scale to deliver services locally. By utilizing surgeons that can drive or fly commercially to donors, we reduce the time and cost to get to the OR.
We have become more efficient across the board, repositioning empty airplanes less, using two airplanes less, and successfully leveraging local surgeons and aircraft to reduce dry run costs. Customers are seeing the benefits of our more efficient end-to-end platform. They're not just saving money, they're also completing more transplants. What's more, our expanding list of preservation device partnerships enables our transplant center customers to execute cases the best way they see fit. We currently stock devices from OrganOx, Bridge to Life, Paragonix, and Traferox at our clinical hubs across the country, enabling seamless utilization by our customers according to their preferences. Our integrated go-to-market strategy is leading to continued share gains in clinical. In addition, Strata has a much larger financial opportunity in these integrated cases, as much as three times versus a transport-only case, weighted more heavily towards clinical revenue. This is a win-win in several ways.
One, our clinicians and perfusion equipment deployed on short trips locally see higher utilization versus transplant center-based resources. In other words, in our system, the same number of surgeons can recover more organs. Two, Strata builds deeper clinical relationships with our customers while shifting mix to our higher margin, higher free cash flow conversion business lines. And three, of course, one of our objectives is to save our customers money. We do this by reducing logistics expenses for dry runs and handling transportation of our staff via ground or commercial air, which we do successfully roughly two-thirds of the time. Though this is a contributor to reduced flight hours per case, it is a worthwhile investment in doing right by our customers that creates a significant long-term competitive advantage for Strata.
Most importantly, by reducing the cost of a dry run, we make it financially possible for our customers to attempt more organ recoveries. A case with only a 50% probability of a successful recovery transforms from a pass to a 50% chance of saving multiple lives. We are really just getting started demonstrating this value proposition to the transplant community, and we are excited about the growth potential in the business over the coming years. We continue to pursue creative opportunities to further improve the efficiency of our model and increase our total addressable market. To that end, in October, we launched with our first customer in our new cardiothoracic surgical locum tenens business line, loaning our surgeons and clinicians to hospitals for non-transplant use cases.
This is a huge new addressable market for us that also serves to further increase the utilization of our surgeons and makes us a more attractive employer. More work means more pay for our team and ultimately better staff retention. Moving to industry trends, the transplant system exhibited above average seasonality in Q3, with deceased donors and heart, liver, and lung transplants falling approximately 7% quarter-over-quarter. While transplant volume continued to grow in the mid-single digit range year-over-year, trip distances fell approximately 10% year-over-year, driven primarily by lungs. As a reminder, lungs moved to continuous distribution in 2023, driving an increase of over 100% in lung distances between 2022 and 2025. Earlier this year, OPTN modified the lung continuous distribution composite allocation score, resulting in a roughly 20% year-over-year decline in lung trip distances in Q3.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
8 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
